Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06, Bloomberg Earnings reports. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. During the same quarter in the prior year, the company earned $1.83 EPS. The business’s revenue was up 12.6% compared to the same quarter last year. Johnson & Johnson updated its FY18 guidance to $8.00-8.20 EPS.
Shares of NYSE:JNJ traded down $2.08 during trading on Tuesday, hitting $129.68. The stock had a trading volume of 7,883,585 shares, compared to its average volume of 7,898,482. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32. The stock has a market cap of $350,440.66, a price-to-earnings ratio of 17.71, a PEG ratio of 2.08 and a beta of 0.74. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.22% of the company’s stock.
Several large investors have recently made changes to their positions in JNJ. Harding Loevner LP purchased a new position in Johnson & Johnson during the second quarter valued at approximately $106,000. IHT Wealth Management LLC raised its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the second quarter valued at approximately $124,000. Financial Gravity Companies Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $143,000. Finally, Delpha Capital Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $166,000. Hedge funds and other institutional investors own 67.23% of the company’s stock.
A number of research firms have recently issued reports on JNJ. Wells Fargo reissued an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target on the stock in a research report on Thursday, January 11th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Finally, BTIG Research reissued a “sell” rating and set a $110.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $144.23.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Announces Earnings Results” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/johnson-johnson-jnj-releases-earnings-results-beats-expectations-by-0-05-eps.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.